Holen Sie sich die Stockscreener-App
7.03
3.17%
-0.23
Handel nachbörslich:
7.02
-0.01
-0.14%
Climb Bio Inc Aktie (CLYM) Neueste Nachrichten
Pharma News: Will Climb Bio Inc benefit from green energy policiesMarket Risk Report & Growth-Oriented Investment Plans - baoquankhu1.vn
Targets Report: Can Climb Bio Inc sustain its profitability2026 Action & Low Risk Profit Maximizing Plans - baoquankhu1.vn
What is HC Wainwright's Forecast for Climb Bio Q1 Earnings? - MarketBeat
Analysts’ Weekly Ratings Updates for Climb Bio (CLYM) - Defense World
Raymond James starts Climb Bio, Inc. (CLYM) at Strong Buy March 2026 - Meyka
Research Analysts Issue Forecasts for Climb Bio Q1 Earnings - Defense World
Climb Bio (NASDAQ:CLYM) Shares Gap Up Following Analyst Upgrade - MarketBeat
Q1 Earnings Forecast for Climb Bio Issued By HC Wainwright - MarketBeat
Raymond James initiates Climb Bio stock coverage with strong buy on renal pipeline - Investing.com UK
Climb Bio (NASDAQ:CLYM) Hits New 52-Week High After Analyst Upgrade - MarketBeat
Climb Bio (NASDAQ:CLYM) Price Target Raised to $15.00 - MarketBeat
Climb Bio (NASDAQ:CLYM) Research Coverage Started at Wedbush - Defense World
Published on: 2026-03-08 04:23:03 - baoquankhu1.vn
Piper Sandler initiates coverage of Climb Bio (CLYM) with overweight recommendation - MSN
Fed Meeting: Is Climb Bio Inc a stock for growth or value investors2025 Biggest Moves & Consistent Income Trade Ideas - baoquankhu1.vn
Climb Bio (NASDAQ:CLYM) Posts Quarterly Earnings Results, Misses Estimates By $0.06 EPS - MarketBeat
Wedbush Raises Price Target for CLYM, Maintains 'Outperform' Rat - GuruFocus
Baird Maintains "Outperform" Rating, Raises Price Target for CLY - GuruFocus
Climb Bio (NASDAQ:CLYM) Price Target Raised to $12.00 - MarketBeat
Climb Bio Stock Pre-Market (+6.4%): Wedbush Initiates at Outperform, $12 Target - Trefis
Investment Recap: What is the Moat Score of Climb Bio Inc2025 Growth vs Value & Real-Time Buy Signal Notifications - baoquankhu1.vn
Wedbush Begins Coverage on Climb Bio (NASDAQ:CLYM) - MarketBeat
Climb Bio Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Updates - Bitget
Wedbush initiates Climb Bio stock with Outperform rating By Investing.com - Investing.com Nigeria
Wedbush initiates Climb Bio stock with Outperform rating - Investing.com India
Wedbush Initiates Climb Bio at Outperform With $12 Price Target - marketscreener.com
Climb 2025 10-K: $0 Revenue, $(0.88) EPS and $59.9M Net Loss - TradingView
CLYM: Net loss narrowed to $59.9M in 2025 as clinical R&D spending accelerated - TradingView
Aug PostEarnings: Does Climb Bio Inc offer margin of safetyJuly 2025 Highlights & Detailed Earnings Play Alerts - baoquankhu1.vn
CLYM Stock Price and Chart — NASDAQ:CLYM - TradingView
Climb Bio, Inc. (NASDAQ:CLYM) Given Consensus Recommendation of "Moderate Buy" by Analysts - MarketBeat
Climb Bio, Inc. (NASDAQ:CLYM) Given Consensus Recommendation of “Moderate Buy” by Analysts - Defense World
Insider Sell Alert: Stephen Thomas Sells 50,000 Shares of Climb Bio Inc (CLYM) - GuruFocus
Climb Bio (NASDAQ:CLYM) Reaches New 12-Month HighStill a Buy? - MarketBeat
Climb Bio Highlights 2025 Data Catalysts, CD19 and APRIL Programs at Oppenheimer Conference - MarketBeat
Climb Bio (CLYM) Price Target Increased by 20.30% to 11.66 - Nasdaq
Proposed 50,000-share sale by CLYM broker (CLYM) - Stock Titan
CLYM: Multiple clinical readouts expected in 2024 for antibody therapies in PMN, ITP, and IgAN - TradingView
CLYM: Five clinical data readouts expected in 2024, with cash runway secured into 2028 - TradingView
Aug Update: What is Fresh Del Monte Produce Incs 5 year growth outlookJuly 2025 Setups & Verified Entry Point Detection - baoquankhu1.vn
CLYM Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Climb Bio’s Stock Run Puts All Eyes On 2026 Trial Data - Finimize
Klein Hersh Recruits Chief Medical Officer for Zag Bio - Hunt Scanlon Media
Climb Bio (CLYM) director sells 100,000 shares in planned trades - Stock Titan
What’s the analyst consensus on Climb Bio Inc.Earnings Beat & Verified Short-Term Trading Plans - mfd.ru
This Taiwan Semiconductor Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Friday - Benzinga
Climb Bio Teases 5 Data Readouts in 2026, Highlights CD19 and APRIL “Sweeper” Programs at Summit - MarketBeat
Piper Sandler initiates Climb Bio stock with Overweight rating, $23 target - Investing.com Canada
CLYM: Five clinical readouts in 2024 and strong cash runway drive autoimmune pipeline progress - TradingView
CLYM (NASDAQ: CLYM) shareholder files to sell 100,000 shares - Stock Titan
Here's Why We're Watching Climb Bio's (NASDAQ:CLYM) Cash Burn Situation - Sahm
0.48%
1.21%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):